TMCI logo

TREACE MEDICAL CONCEPTS INC

TMCINASDAQ
๐Ÿ† #2943 by market capEarnings Nov 5US Equity
$4.51โ–ผ $0.22 (โˆ’4.85%)
Live
1hโ–ฒ 0.0%
24hโ–ผ 4.8%
7dโ–ผ 5.7%
14dโ–ฒ 11.9%
30dโ–ผ 1.5%
1yโ–ผ 31.0%
๐ŸฆMarket Cap
$293M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-1.7%
Declining
๐Ÿ“ŠGross Margin
79.7%
High
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
1.5x
Cheap
Otter Score
65
Fair

Trading Snapshot

Day Range
$4.44 โ€“ $4.58
52-Week Range
$1.17 โ€“ $7.78
Volume
$3.28B
Avg Volume
$3.09B
Shares Outstanding
64.9M
Next Earnings
Sep 25, 2026

Fundamentals Snapshot

Annual Revenue
$213M
Last Q Revenue
$45M
P/E Ratio
โ€”
P/S Ratio
1.5x
EPS (TTM)
$-0.96
Dividend Yield
โ€”

Why Investors Own TMCI

  • โœ“High-growth profile โ€” revenue up +22.1% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 30% gross margin and 26% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$213Mโ–ฒ +20.9% YoY
Gross Margin (TTM)
30.2%โ–ฒ +2.1% YoY
Operating Income (TTM)
$55Mโ–ฒ +20.9% YoY
Free Cash Flow (TTM)
$56Mโ–ฒ +20.9% YoY

About TREACE MEDICAL CONCEPTS INC

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
65/100

Analyst Ratings

โ“˜
Consensus
Hold
10 analysts
Strong Buy0
Buy1
Hold5
Sell2
Strong Sell2
Ratings as of Aug 2026

Latest News & Updates

๐Ÿš€
Benzingaยท1d ago

Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5

Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $4 to $5.

SeekingAlphaยท4d ago

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call August 7, 2026 8:00 AM EDTCompany ParticipantsTrip TaylorJohn Treace - Founder, Chairman &...

ChartMillยท5d ago

Treace Medical Concepts (NASDAQ:TMCI) Rises as Q2 Loss Narrows, Revenue Matches Estimates

Treace Medical Q2: Revenue $45.4M in line, EPS -$0.24 beats -$0.30 estimate. FY guidance raised, stock up 9% pre-market.

๐Ÿš€
Benzingaยท5d ago

Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate

Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share

๐Ÿ›ฐ๏ธ
Benzingaยท5d ago

Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est

Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.

๐ŸŒŒ
Benzingaยท27d ago

Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $4

Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $2 to $4.